Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
3 studies found for:    PROSTATE CANCER, HEREDITARY, 2
Show Display Options
Rank Status Study
1 Active, not recruiting Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
Conditions: Basal-Like Breast Carcinoma;   BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Breast Carcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Hereditary Breast and Ovarian Cancer Syndrome;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Progesterone Receptor Negative;   Prostate Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Solid Neoplasm;   Triple-Negative Breast Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Veliparib
2 Recruiting Prostate Cancer Screening Among Men With High Risk Genetic Predisposition
Conditions: BRCA1 Syndrome;   BRCA2 Syndrome;   Lynch Syndrome
Interventions: Other: PSA;   Other: IPSS questionnaire;   Other: DRE (Digital Rectal Examination );   Other: urine flow and residual;   Procedure: a multiparametric prostate MRI;   Procedure: trans-rectal ultra-sound guided prostate biopsy
3 Recruiting A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer
Conditions: Ovarian Cancer;   Breast Cancer;   Prostate Cancer
Intervention: Drug: LY2606368

Indicates status has not been verified in more than two years